Seeking Alpha

Sanofi (SNY) wins U.S. FDA approval for Aubagio, a pill designed to treat multiple sclerosis,...

Sanofi (SNY) wins U.S. FDA approval for Aubagio, a pill designed to treat multiple sclerosis, making it the second oral therapy that will be available on the U.S. market. The drug will compete with Novartis' (NVS) Gilenya, an oral pill which was approved by the FDA in 2010.
Comments (1)
  • Goeleven
    , contributor
    Comments (629) | Send Message
     
    Finaly SNY got FDA approval for Aubagio. Not so good for NVS
    13 Sep 2012, 06:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector